Valuation : Erasca, Inc.

Market Cap 5.66B 4.87B 4.58B 4.19B 7.83B 535B 7.86B 54.17B 21.02B 274B 21.26B 20.8B 884B P/E 2026 *
-16.4x
P/E 2027 * -24.6x
Enterprise Value 4.81B 4.14B 3.9B 3.56B 6.66B 455B 6.68B 46.06B 17.87B 233B 18.08B 17.68B 751B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
90.52%
Yield 2026 *
-
Yield 2027 * -
1 day-0.43%
1 week-10.21%
Current month-9.45%
1 month-11.92%
3 months+22.00%
6 months+7.08%
Current year+335.22%
1 week 15.77
Extreme 15.77
18.03
1 month 15.77
Extreme 15.77
20.4
Current year 3.36
Extreme 3.36
24.28
1 year 1.52
Extreme 1.525
24.28
3 years 1.01
Extreme 1.01
24.28
5 years 1.01
Extreme 1.01
24.47
10 years 1.01
Extreme 1.01
24.47
Manager TitleAgeSince
Chief Executive Officer 54 28/02/2019
Director of Finance/CFO 43 06/01/2021
Chief Tech/Sci/R&D Officer 66 09/08/2026
Director TitleAgeSince
Chairman 54 30/09/2018
Director/Board Member 79 31/05/2018
Director/Board Member 58 01/07/2018
Date Insider Type Main position Quantity % Market Cap. Importance
10/08/26 Free

Chief Technology Officer

1,300,000 0.3745%
26/06/26 Free

Director

29,888 0.0096%
01/04/26 Exercice

General Counsel

240,000 0.0772%
Change 5-day change 1-year change 3-year change Capi.($)
-0.43%-10.21%+993.92%+525.10% 5.66B
-2.54%-2.84%-1.90%+14.52% 48.93B
-0.40%+1.03%+439.20%+499.20% 45.01B
-1.42%+2.30%+45.46%+19.36% 44.07B
-1.22%-2.31%+12.40%+71.48% 40.73B
+0.53%-1.36%+16.04%+48.23% 33.52B
-0.21%+9.14% - - 17.77B
-0.35%-1.56%+22.59%+116.19% 16.5B
-1.01%+0.50%+15.83%+27.98% 14.67B
-1.65%-1.03%+77.75%+37.63% 13.77B
Average -0.87%-0.54%+180.14%+151.08% 28.07B
Weighted average by Cap. -1.02%-0.10%+114.23%+130.79%

Financials

2026 *2027 *
Net sales - -
Net income -322M -277M -261M -238M -445M -30.38B -446M -3.08B -1.19B -15.59B -1.21B -1.18B -50.21B -228M -196M -185M -169M -316M -21.54B -317M -2.18B -847M -11.05B -857M -838M -35.61B
Net Debt -849M -730M -687M -628M -1.17B -80.12B -1.18B -8.12B -3.15B -41.11B -3.19B -3.12B -132B -762M -655M -617M -563M -1.05B -71.92B -1.06B -7.29B -2.83B -36.9B -2.86B -2.8B -119B
Logo Erasca, Inc.
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.
Employees
103
Date Price Change Volume
04/09/26 US$16.19 -0.43% 2,055,114
03/09/26 US$16.26 -0.67% 3,762,016
02/09/26 US$16.37 -2.33% 5,121,428
01/09/26 US$16.76 -6.26% 6,708,100
31/08/26 US$17.88 -0.83% 4,766,259
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
16.19USD
Average target price
24.11USD
Spread / Average Target
+48.93%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ERAS Stock